Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
GLMD Stock Summary
Top 10 Correlated ETFs
GLMD
In the News
Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stock at a price of $2.28 per share.
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equity investment in OnKai.
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD ) Q4 2021 Earnings Conference Call May 2, 2022 8:30 AM ET Company Participants Allen Baharaff - President and CEO Yohai Stenzler - Chief Accounting Officer Conference Call Participants Steven Seedhouse - Raymond James Kristen Kluska - Cantor Fitzgerald Naz Rahman - Maxim Group Operator Good day and welcome to the Galmed Conference Call to discuss Financial Results for the Fourth Quarter and Year-end 2021.
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript
Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER is a five amino acid in a specific sequence originally isolated from synovial fluid of rheumatoid arthritis patients.
Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
TEL AVIV, Israel, Aug. 19, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the publication in The Journal of Autoimmunity for its IND ready compound, Amilo-5MER entitled: "MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-Serum Amyloid A.
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript
GLMD Stock Increases Over 4% Pre-Market: Why It Happened
The stock price of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) increased by over 4% pre-market. This is why it happened.
FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the FDA agreed with its plan to use Aramchol meglumine (in lieu of Aramchol free acid) in its Phase 3 ARMOR study without the need to conduct additional nonclinical and clinical studies other than planned limited pharmacology studies relating to Aramchol meglumine.
GLMD Financial details
GLMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.69 | 0 | 0 | 0 | 0 | |
Net income per share | -8.15 | -13.17 | -19.46 | -19.48 | -11.08 | |
Operating cash flow per share | -7.46 | -10.61 | -18.53 | -20.06 | -11.04 | |
Free cash flow per share | -7.54 | -10.62 | -18.56 | -20.06 | -11.04 | |
Cash per share | 74.59 | 53.63 | 35.87 | 21.23 | 8.22 | |
Book value per share | 72.69 | 49.62 | 31.12 | 18.6 | 8.01 | |
Tangible book value per share | 72.69 | 49.62 | 31.12 | 18.6 | 8.01 | |
Share holders equity per share | 72.69 | 49.62 | 31.12 | 18.6 | 8.01 | |
Interest debt per share | 0 | 0.27 | 0.17 | 0.17 | 0.15 | |
Market cap | 8.26M | 8.14M | 4.41M | 2.98M | 838.09K | |
Enterprise value | -15.9M | -7.44M | -2.32M | 329.51K | -1.13M | |
P/E ratio | -0.84 | -0.44 | -0.16 | -0.09 | -0.05 | |
Price to sales ratio | 4.05 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.92 | -0.54 | -0.17 | -0.09 | -0.05 | |
PFCF ratio | -0.91 | -0.54 | -0.17 | -0.09 | -0.05 | |
P/B Ratio | 0.09 | 0.12 | 0.1 | 0.1 | 0.06 | |
PTB ratio | 0.09 | 0.12 | 0.1 | 0.1 | 0.06 | |
EV to sales | -7.8 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 1.54 | 0.33 | 0.08 | -0.01 | 0.07 | |
EV to operating cash flow | 1.76 | 0.5 | 0.09 | -0.01 | 0.06 | |
EV to free cash flow | 1.74 | 0.5 | 0.09 | -0.01 | 0.06 | |
Earnings yield | -1.19 | -2.28 | -6.26 | -10.7 | -22.16 | |
Free cash flow yield | -1.1 | -1.84 | -5.97 | -11.02 | -22.08 | |
Debt to equity | 0 | 0.01 | 0 | 0.01 | 0 | |
Debt to assets | 0 | 0 | 0 | 0.01 | 0 | |
Net debt to EBITDA | 2.34 | 0.7 | 0.22 | 0.08 | 0.12 | |
Current ratio | 33.41 | 11.02 | 6.47 | 6.13 | 4.76 | |
Interest coverage | 0 | -678.06 | -974.52 | -764.67 | -82.1 | |
Income quality | 0.92 | 0.73 | 0.91 | 1.01 | 1.04 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.18 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 4.08 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.04 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.23 | -0.34 | -1.13 | -0.26 | -0.11 | |
Stock based compensation to revenue | 0.87 | 0 | 0 | 0 | 0 | |
Graham number | 115.46 | 121.27 | 116.74 | 90.29 | 44.68 | |
ROIC | -0.12 | -0.29 | -0.65 | -1.05 | -1.36 | |
Return on tangible assets | -0.11 | -0.24 | -0.53 | -0.87 | -1.12 | |
Graham Net | 72.38 | 38.97 | 29.16 | 17.74 | 6.44 | |
Working capital | 87.7M | 69.5M | 43.8M | 30.18M | 11.63M | |
Tangible asset value | 87.89M | 69.85M | 44.15M | 30.5M | 13.42M | |
Net current asset value | 87.7M | 69.14M | 43.58M | 29.95M | 11.59M | |
Invested capital | 0 | 0.01 | 0 | 0.01 | 0 | |
Average receivables | 103K | 439K | 819.5K | 968.5K | 624.5K | |
Average payables | 2.05M | 3.91M | 6.52M | 5.96M | 3.72M | |
Average inventory | -50K | -13.97M | -15.87M | -2.37M | -409K | |
Days sales outstanding | 9.13 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 62.56K | 65.94K | 42.33K | 26.7K | |
Days of inventory on hand | 0 | -291.35K | -35.63K | -8.1K | 1.19K | |
Receivables turnover | 39.96 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
Inventory turnover | 0 | 0 | -0.01 | -0.05 | 0.31 | |
ROE | -0.11 | -0.27 | -0.63 | -1.05 | -1.38 | |
Capex per share | -0.07 | -0.01 | -0.03 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -3.2 | -1.68 | -0.99 | -0.95 | -0.24 | |
Operating cash flow per share | -1.85 | -2.39 | -1.01 | -0.81 | -0.35 | |
Free cash flow per share | -1.85 | -2.4 | -1.01 | -0.81 | -0.35 | |
Cash per share | 11.44 | 8.2 | 7.23 | 5.55 | 2.13 | |
Book value per share | 9.38 | 7.99 | 7.14 | 6.28 | 2.49 | |
Tangible book value per share | 9.38 | 7.99 | 7.14 | 6.28 | 2.49 | |
Share holders equity per share | 9.38 | 7.99 | 7.14 | 6.28 | 2.49 | |
Interest debt per share | 0.07 | 0.14 | -0.1 | 0 | 0 | |
Market cap | 522.26K | 840.11K | 717.46K | 5.02M | 3.87M | |
Enterprise value | -3.45M | -1.13M | -954.54K | 4.01M | 2.39M | |
P/E ratio | -0.02 | -0.07 | -0.11 | -0.79 | -0.66 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.17 | -0.21 | -0.42 | -3.68 | -1.78 | |
PFCF ratio | -0.17 | -0.21 | -0.42 | -3.68 | -1.78 | |
P/B Ratio | 0.03 | 0.06 | 0.06 | 0.48 | 0.25 | |
PTB ratio | 0.03 | 0.06 | 0.06 | 0.48 | 0.25 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.64 | 0.46 | 0.48 | -2.16 | -1.64 | |
EV to operating cash flow | 1.11 | 0.28 | 0.56 | -2.94 | -1.1 | |
EV to free cash flow | 1.11 | 0.28 | 0.56 | -2.94 | -1.1 | |
Earnings yield | -10.3 | -3.37 | -2.31 | -0.32 | -0.38 | |
Free cash flow yield | -5.96 | -4.79 | -2.36 | -0.27 | -0.56 | |
Debt to equity | 0.01 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 0.74 | 0.81 | 0.84 | 0.54 | 1.02 | |
Current ratio | 4.07 | 4.76 | 4.58 | 3.59 | 6.79 | |
Interest coverage | -179.33 | -12.89 | 11.64 | 0 | -293.6 | |
Income quality | 0.58 | 1.52 | 0.93 | 0.86 | 1.48 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -0.11 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 26 | 17.4 | 12.59 | 11.58 | 3.63 | |
ROIC | -0.34 | -0.19 | -0.15 | -0.18 | -0.09 | |
Return on tangible assets | -0.26 | -0.17 | -0.11 | -0.12 | -0.08 | |
Graham Net | 8.91 | 6.43 | 5.85 | 4.12 | 1.74 | |
Working capital | 15.45M | 11.63M | 10.03M | 7.06M | 12.11M | |
Tangible asset value | 15.75M | 13.42M | 11.99M | 10.55M | 15.55M | |
Net current asset value | 15.36M | 11.59M | 10.03M | 7.06M | 12.11M | |
Invested capital | 0.01 | 0 | 0 | 0 | 0 | |
Average receivables | 882.5K | 637.5K | 346K | 454.5K | 555.5K | |
Average payables | 3.42M | 3.65M | 2.41M | 2.2M | 1.81M | |
Average inventory | 0 | 57K | 113.66K | 113.93K | -845.73K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 25.6K | 25.49K | 21.4K | 0 | |
Days of inventory on hand | 0 | 1.14K | 1.27K | 1.15K | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0.08 | 0.07 | 0.08 | 0 | |
ROE | -0.34 | -0.21 | -0.14 | -0.15 | -0.09 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
GLMD Frequently Asked Questions
What is Galmed Pharmaceuticals Ltd. stock symbol ?
Galmed Pharmaceuticals Ltd. is a IL stock and trading under the symbol GLMD
What is Galmed Pharmaceuticals Ltd. stock quote today ?
Galmed Pharmaceuticals Ltd. stock price is $0.3315 today.
Is Galmed Pharmaceuticals Ltd. stock public?
Yes, Galmed Pharmaceuticals Ltd. is a publicly traded company.